Aquestive(US:AQST) TMX Newsfile·2026-03-21 10:56Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's NDA for Anaphylm [2][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Aquestive between June 16, 2025, and January 8, 2026, to discuss their legal rights [1]. - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Aquestive and its executives failed to disclose significant deficiencies in the NDA for Anaphylm, particularly regarding human factors in the use of its sublingual film [5]. Group 2: Stock Price Impact - Following the announcement of deficiencies in the NDA by the FDA on January 9, 2026, Aquestive's stock price dropped by $2.30 per share, representing a 37.04% decline, closing at $3.91 per share [6]. Group 3: Firm Background and Outreach - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [4]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Aquestive's conduct [8].